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Abstract
Studies investigating dynamic susceptibility contrast magnetic resonance imaging–determined relative cerebral
blood volume (rCBV) maps as a metric of treatment response assessment have generated conflicting results.
We evaluated the potential of various analytical techniques to predict survival of patients with glioma treated with
chemoradiation. rCBV maps were acquired in patients with high-grade gliomas at 0, 1, and 3 weeks into chemo-
radiation therapy. Various analytical techniques were applied to the same cohort of serial rCBV data for early assess-
ment of survival. Three different methodologies were investigated: 1) percentage change of whole tumor statistics
(i.e., mean, median, and percentiles), 2) physiological segmentation (low rCBV, medium rCBV, or high rCBV), and 3)
a voxel-based approach, parametric response mapping (PRM). All analyses were performed using the same tumor
contours, which were determined using contrast-enhanced T1-weighted and fluid attenuated inversion recovery
images. The predictive potential of each response metric was assessed at 1-year and overall survival. PRM was
the only analytical approach found to generate a response metric significantly predictive of patient 1-year survival.
Time of acquisition and contour volume were not found to alter the sensitivity of the PRM approach for predicting
overall survival. We have demonstrated the importance of the analytical approach in early response assessment
using serial rCBV maps. The PRM analysis shows promise as a unified early and robust imaging biomarker of treat-
ment response in patients diagnosed with high-grade gliomas.
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Introduction
Glioblastoma multiforme is the most common form of brain malig-
nancy in adult patients, with approximately 53% of patients with
primary brain tumors afflicted by this subtype [1]. Even with advance-
ments in the clinical management of these patients, assessment of
therapeutic response continues to be based on late or serial changes
in tumor volume as measured by computed tomography or magnetic
resonance imaging (MRI) [2,3]. The Macdonald criteria have been the
standard for response assessment over the past 20 years [2], with
changes in tumor volume of interest assessed on T1-weighted post-
gadolinium (Gd-VOI) images acquired after the completion of chemo-
radiotherapy. It has become increasingly apparent that significant
limitations exist in the Macdonald criteria, such as pseudoprogression
that occurs in 20% to 30% of all newly diagnosed glioma patients treated
with chemoradiation [4,5]. In 2010, the Response Assessment inNeuro-
Oncology (RANO) Working Group sets new guidelines for response
assessment in patients with glioma. In recognition that contrast
enhancement is nonspecific and may not always serve as a surrogate
of tumor response, these new assessment criteria incorporate non-
enhancing imaging modalities such as fluid attenuated inversion recov-
ery (FLAIR) images in addition to gadolinium-enhanced T1-weighted
(T1-Gd) images to delineate brain tumors [3]. Although these new
guidelines compensate for some of the deficiencies of the Macdonald
criteria, RANO continues to rely on changes in tumor volume as deter-
mined on anatomic images that inevitably will introduce errors associ-
ated with interobserver variability [6]. To account for this, the guidelines
also stipulate that it is permissible to acquire interval exams if radio-
graphic changes are equivocal. For those patients nonresponsive to
therapy, this would delay any change in their treatment management.
With a median survival of only 14 months [7], such a delay could prove
detrimental to the overall survival of the patient.
Functional imaging techniques show promise for diagnosis and
assessment of treatment response of patients with cancer [8–11].
The relative cerebral blood volume (rCBV) as determined by dynamic
susceptibility contrast (DSC) MRI has been shown to correlate with
treatment efficacy in patients with glioma, providing a possible alter-
native to gross volumetric evaluation of tumor response to therapy
[12,13]. Many analytical techniques have been proposed for eval-
uating rCBV as an early response metric to treatment. The conven-
tional approach for analyzing MRI parameters is to determine the
percentage change in a summary statistic over the tumor VOI, which
may be delineated using qualitative imaging such as T1-Gd and
FLAIR images. These summary statistics may include the histogram
mean, median, or even percentile of the parameter [14,15]. We have
proposed a physiologically based approach where relative tumor vol-
umes are determined from the segmentation of the tumor histogram
based on known physiological values. The percentage changes in these
relative volumes are determined from serially imaging examinations
prior and following treatment initiation [12]. Finally, we have devel-
oped a new technique, called parametric response mapping (PRM),
that monitors on a voxel-by-voxel basis regional changes in tumor
perfusion for early assessment of therapeutic response in patients with
glioma [16]. The PRM approach, when applied to rCBV (PRMrCBV)
within the enhancing tumor as contoured on T1-Gd images, has been
shown to be highly predictive of survival as early as 1 week post-
treatment initiation as well as differentiating pseudoprogression from
true progression [12,16,17].
There exists a wide variety of techniques for analyzing rCBV data.
The extensive research devoted to investigating rCBV as a surrogate
imaging biomarker of glioma response to therapy highlights the need
for consensus on the optimal method for analyzing this imaging
technique. In this study, we investigate the impact of the analytic
method when applied to rCBV data for assessing therapeutic induced
response in patients with glioma. In addition, we evaluated for each
metric the effect of both 1) the VOI used, Gd-VOI versus FLAIR-
VOI, and 2) the time of MRI examination post-treatment initiation
on the metrics predictive value of 1-year and overall survival in a cohort
of patients with glioma.
Materials and Methods
Patients
Patients with pathologically proven grade III/IV gliomas (n = 8/36,
respectively) were enrolled on a protocol of intratreatment MRI.
Informed consent was obtained, and images and medical record use
were approved by the Institutional Review Board. Forty-four patients
were evaluated pre-therapy and 1 and 3 weeks after initiation of
chemoradiation. This cohort, or a part of this cohort of patients,
has been used previously in published work investigating the prog-
nostic value of PRM applied to the individual parameters of apparent
diffusion coefficient [18] and rCBV [16] and a composite model of
PRM applied to these two parameters [19].
Radiotherapy was delivered over 6 weeks using standard tech-
niques with a 2.0- to 2.5-cm margin on either the enhancing region
on Gd-enhanced scans or the abnormal signal on T2-weighted scans
to 46 to 50 Gy with the central gross tumor treated to a final median
dose of 70 Gy.
MRI Scans
MRI scans were performed 1 week before and 1 and 3 weeks
after initiation of therapy. All images were acquired on either a 1.5-T
MRI system (General Electric Medical Systems, Milwaukee, WI; n =
30 patients) or a 3-T Philips Achieva system (Philips Medical Systems,
Best, The Netherlands; n = 14 patients). The MRI protocol included
FLAIR, DSC T2*-weighted imaging, and contrast-enhanced T1-
weighted imaging.
Following the FLAIR acquisition, Gd diethylenetriamine penta-
acetic acid was injected intravenously with a dose of 0.05 to 0.1 ml/kg
to decrease the blood-brain barrier leakage impact on the rCBVmeasure-
ment as recommended by Paulson and Schmainda [20]. Subsequently,
a T1-Gd image was acquired. For DSC imaging, 14 to 20 slices of
dynamic T2*-weighted images were acquired by a gradient-echo echo-
planar imaging pulse sequence [repetition time (TR) = 1.5 to 2 seconds,
echo time (TE) = 50 to 60 milliseconds, field of view = 220 × 220 mm2,
matrix = 128 × 128, flip angle = 60°, sensitivity encoding (SENSE) fac-
tor = 3 in phase-encode anterior-posterior direction and 4- to 6-mm
thickness and 0-mm gap]. DSC-MRIs were acquired before and fol-
lowing a second dose of Gd diethylenetriamine pentaacetic acid, which
was injected intravenously with a dose of 0.05 to 0.1 ml/kg as a bolus
using a power injector at a rate of 2ml/s, followed immediately by 15ml
of saline flush at the same rate.
CBV maps were generated from DSC T2*-weighted images as
described previously [12]. To assess differences in tumor blood vol-
ume during radiotherapy and between patients, CBV maps were nor-
malized to values within white matter regions contralateral to the
tumor to generate the rCBV. For normalization, we used those white
matter VOIs that were contralateral to the tumor, had received <30 Gy
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accumulated dose, and were as large as possible while still avoiding
regions with susceptibility artifacts and partial volume averaging.
Image Registration
All image data were registered to pre-treatment T1-Gd images
using mutual information as an objective function and Nelder-Mead
simplex as an optimizer [21]. Automatic registration of different and
similar weighted serial MRI scans for the same patient was performed
assuming a rigid body–geometry relationship. Following registration,
brain tumor VOIs were manually contoured by a neuroradiologist
over regions of the tumor that are hyperintense on FLAIR (FLAIR-
VOI) and on T1-Gd images (Gd-VOI).
Image Analysis
Three post-processing approaches were assessed for monitoring
therapeutic response using VOIs contoured on FLAIR and T1-Gd
images. A statistical summary approach was performed by calculating
the percentage change of the rCBV mean and median. Additionally,
we evaluated the percentage change of the percentiles of the histo-
gram, which also include, in increments of 10% [22], 25th, 75th,
and 95th percentiles [23] (Figure 1A). We then evaluated a physio-
logically based approach. In brief, tumor rCBV histograms pre-
treatment and mid-treatment were separated into three segments
using discrete thresholds previously defined as >4 for the high rCBV
region (approximately 2 SD greater than the mean in gray matter),
1.7 to 4 in the intermediate rCBV, and <1.7 but >0.2 (2 SD less
than the mean of white matter) in the low rCBV region [12]
(Figure 1B). Then, the percentage changes over time of the volume
fraction of these three regions were calculated and named as follows:
high rCBV, medium rCBV, and low rCBV, respectively. The final
approach analyzed is the PRM voxel-based approach [16]. Briefly,
PRM was performed on spatially registered serial rCBV maps by cal-
culating the difference in the rCBV values of each voxel within the
tumor. Voxels were designated in the following three categories:
increased rCBV (PRMrCBV+, red voxels), decreased rCBV (PRMrCBV−,
blue voxels), and no change (PRMrCBV0, green voxels; Figure 1C). The
threshold that designates a significant change in rCBV within a voxel
beyond the effect of imaging noise was defined as ±1.2 as previously
described [16]. In brief, thresholds were determined empirically from
seven randomly selected subjects. For each subject, healthy contralateral
brain tissue was contoured to generate registered rCBV values pre-
treatment and mid-treatment. The 95% confidence intervals were
determined by linear least-squares regression analysis and averaged over
all seven subjects.
Statistical Analysis
All parameters were analyzed for each mid-treatment examination
and VOI. A paired t test was used to 1) compare tumor volumes
contoured on FLAIR and T1-Gd and 2) to compare tumor volumes as
defined separately by FLAIR-VOI and Gd-VOI over time (week 0 vs
week 1, week 0 vs week 3, and week 1 vs week 3). We performed
receiver operating characteristic (ROC) curve analysis for correlation
of the imaging parameters with subject survival 1 year from diagno-
sis. The area under the curve (AUC) was obtained to distinguish
which continuous variables were predictive measures of outcome.
For parameters that were found to be statistically significant by ROC
analysis, optimal cutoffs were determined from ROC curves based on
optimal values of sensitivity and specificity. The patient population was
then stratified on the basis of the optimal cutoffs for each parameter.
Overall survival was assessed for each parameter using Kaplan-Meier
survival curves and the log-rank test or Cox regression analysis for
multivariate analyses. All statistical computations were performed with
a statistical software package (SPSS Software Products, Chicago, IL),
and results were declared statistically significant at the two-sided 5%
comparison-wise significance level (P < .05).
Results
Patient Population
A total of 44 subjects with high-grade glioma were accrued for this
prospective study. Kaplan-Meier analysis revealed that the overall
Figure 1. Schematic of histogram-based approach methods. (A) Statistical histogram-based segmentation consists of measuring the
percentiles in increments of 10% plus 25th, 75th, and 95th percentiles. (B) Physiological histogram-based segmentation consists of
measuring the tumor volume fraction with low rCBV (2 SD less than the mean of white matter), medium rCBV, or high rCBV (approx-
imately 2 SD greater than the mean in gray matter) values. (C) Serial rCBV maps undergo digital image post-processing and analysis that
involves registration of images before and during treatment. Once spatially aligned, individual voxels within the tumor are presented
using a three-color overlay and are classified as unchanged (green), increased (red), or decreased (blue) rCBV following treatment
initiation. These data can also be presented in a scatterplot and quantified over the entire tumor volume by summing all voxels within
a classification and normalizing by the total tumor volume to generate relative volumes for each class.
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median survival for this patient population was 13.1 months, with
52.3% of the population realizing 1-year survival.
Delineation and Characteristics of Tumor Volumes by MRI
Shrinkage or growth of the tumor during the time between scans
may have occurred; however, for this patient population, no statistical
changes in tumor volume were observed between week 0 and weeks 1
and 3 for Gd-VOI (P = .89 and P = .38, respectively) and between
week 0 and week 3 for FLAIR-VOI (P = .12). Nevertheless, we
observed a statically increase of the tumor size using the FLAIR-
VOI between week 0 and week 1 (96 ± 71 versus 104 ± 84 cm3,
P = .03). Irrespective of the time of examination, mean tumor volume
was statistically larger using the FLAIR-VOI compared to the Gd-VOI
(FLAIR-VOI: 96 ± 71, 104 ± 84, and 105 ± 56 cm3 versus Gd-VOI:
37 ± 29, 37 ± 31, and 35 ± 27 cm3; before and 1 and 3 weeks after
treatment onset, respectively; P < .001). In addition, we observed that
tumor histograms were highly dependent on the VOI (Figure 2,
right column; red versus blue curve).
Correlation of Image Analysis with Treatment Outcome
One-year survival was individually assessed for each metric, at
each time point and VOI, using an ROC curve analysis (Table 1).
As previously observed, PRMrCBV− at 1 and 3 weeks mid-treatment us-
ing the Gd-VOI was predictive of survival at 1 year (Table 1) [16]. A
new finding was that PRMrCBV− based on the larger FLAIR-VOI was
also predictive at weeks 1 and 3 (Table 1). In contrast, all statistically
and physiologically based parameters failed to predict 1-year survival,
and no further analysis was performed on these metrics (Table 1).
Among all the failed metrics, only the low rCBV value using the
FLAIR-VOI at week 3 mid-treatment was at the limit of significance
(P = .05; Table 1).
Figures 3 and 4 provide representative PRMmaps and corresponding
scatterplots from therapeutically responding and nonresponding
patients as determined by 1-year survival. PRM analyses for these two
patients are presented for each time point during treatment and VOIs
used in this study. For a representative responder patient, the relative
volume of tumor with a significant drop in rCBV over time
(PRMrCBV−) was observed to be low for all time point VOIs used with
a range of 1.3% to 1.8% (Figure 3, A–D, blue dots). In contrast, for a
representative nonresponding patient, considerablymore tumor volume
was classified as PRMrCBV− regardless of VOI and time point range was
14.4% to 26% (Figure 5, blue dots). This increase of PRMrCBV− values
corresponds to a decrease of rCBV within these voxels (blue voxels in
Figures 3 and 4) during therapy.
Across the four conditions of two intervals (1 and 3 weeks) and
VOIs (Gd and FLAIR), the optimal cutoffs for PRMrCBV− to predict
patient overall survival ranged from 4.6% to 6.8% that deviated by
only 2.2% from the 6.8% previously reported [16] (Table 2). Sub-
sequently, we used 5.9% (mean across the four optimal cutoffs) as
the cutoff to stratify all patients within the population. The Kaplan-
Meier survival curves and results from the log-rank tests are presented
Figure 2. Representative T1-weighted post-Gd (left), FLAIR (middle), and rCBV maps (right) of a patient with glioblastoma at−1 (A), 1 (B),
and 3 weeks (C) post-treatment initiation. Red and blue contours depict post-Gd T1-weighted and FLAIR imaging tumor volumes, respec-
tively. The tumor histogram for rCBV is depicted using either Gd-VOI (red curves) or FLAIR-VOI (blue curves) obtained−1 (A), 1 (B), or 3weeks
(C) after treatment initiation.
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for PRMrCBV− analysis at weeks 1 and 3 for the T1-Gd and FLAIR-
VOIs (Figure 5). Each of the four PRMrCBV− graphs shows similar pre-
dictive value for the imaging biomarker as each approach was able to
predict significantly different patient outcomes irrespective of the time
the post-treatment rCBV map was acquired or the VOI used. Patients
identified as responders by PRM irrespective of the examination time
lived significantly longer compared to those identified as nonresponders
(Figure 5). Although the parameter low rCBV, as defined by the
physiologically based approach, using the FLAIR-VOI at week 3 mid-
treatment did not fall within our criteria, nevertheless additional anal-
ysis was performed to assess predictive value for overall survival. Using a
Kaplan-Meier analysis and log-rank test, this parameter was weakly
predictive of overall survival (P = .024; data not show).
Bivariate Cox regression analyses were performed to compare low
rCBV against PRMrCBV− using the same VOI at the same examina-
tion time (i.e., FLAIR-VOI at 3 weeks). We observed that only the
dichotomized variable of PRMrCBV−, obtained using the 5.9% cutoff,
was required to fit the statistical model to the survival data (P = .002).
Low rCBV, dichotomized using the optimal cutoff of −2.2%, contrib-
uted to the Cox regression model (P = .2). In addition, we performed a
multivariate Cox regression analysis to assess an optimal examination
time and VOI for PRM analysis. Comparing the four different
PRMrCBV− graphs, dichotomized using the mean cutoff of 5.9%
where all parameters were entered into the statistical model, did not
result in a single significant parameter (P > .2).
Discussion
High-grade gliomas are markedly heterogeneous in their morphol-
ogic and genetic nature [24,25]. As such, they demonstrated a spa-
tially heterogeneous response to cytotoxic and radiation therapies
with tumor regions developing elevated levels of edema, necrosis,
and even angiogenesis, adding difficulty in ascertaining treatment
efficacy [26]. Advanced quantitative MRI techniques, such as
DSC-MRI, have shown promise as a robust imaging technique for
grading and response monitoring of tumors by focusing principally
on a specific physiological feature of the tumor, in this case tumor
blood volume [15,27]. Although physiological changes within the
tumor following therapy can be visualized by quantitative MRI, the
use of these techniques as a surrogate biomarker of patient survival
continues to be hampered due to uncertainties in knowing how to
optimally analyze the data to provide for the most predictive metric.
The traditional method of analyzing quantitative images is to cal-
culate a scalar quantity, e.g., mean or median, that represents the
physiological state of the entire tumor volume at a given time point.
A positive or negative response of the tumor following a therapeutic
intervention can be inferred from the percentage change in the quan-
titative scalar value, thus providing a biomarker that can be tested as
a surrogate of patient survival and translated as a clinical end point
[13,15,28–30]. Although these techniques can be applied quickly
and easily by simply contouring the tumor volume, the metrics pro-
vided in our study failed to yield an accurate biomarker of response
that can predict survival. One fundamental reason for this is that
histogram-based approaches, whether statistical or physiological in
nature, rely on tumor values where the sensitivity of the metric
may attenuate consequent of the underlying heterogeneous response
of the tumor mass. In this regard, we found that histogram-based
techniques for image analysis showed negligible changes in rCBV
when an increase in metric value in one tumor region was offsetTa
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Figure 3. PRMrCBV of a patient responsive to therapy with an overall survival of 22 months. Representative slice of PRMrCBV color-coded
VOI (A, C: Gd-VOI and B, D: FLAIR-VOI) superimposed onto an rCBV map (left) and the corresponding quantitative scatterplot analysis
(right) showing the distribution or rCBV at baseline compared with mid-time treatment (A, B: week 1 and C, D: week 3). The values of
PRMrCBV+, PRMrCBV0, and PRMrCBV− of this patient (corresponding to the relative tumor volume of red, green, and blue voxel pairs
plotted as dots, respectively) are presented in each scatterplot.
Figure 4. PRMrCBV of a patient nonresponsive to therapy with an overall survival of 2.9 months. Representative slice of PRMrCBV color-
coded VOI (A, C: Gd-VOI and B, D: FLAIR-VOI) superimposed onto an rCBV map (left) and the corresponding quantitative scatterplot
analysis (right) showing the distribution or rCBV at baseline compared with mid-time treatment (A, B: week 1 and C, D: week 3). For each
scatterplot, the values of PRMrCBV+, PRMrCBV0, and PRMrCBV− of this patient (corresponding to the relative tumor volume of red, green,
and blue voxel pairs plotted as dots, respectively) are presented.
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by a decrease in another spatially distinct region. Assessing therapeutic
response in patients with glioma using apparent diffusion coefficient
(ADC) maps, Moffat et al. observed that tumor reaction to cytotoxic
treatment was spatially dependent. This led to the development of the
first voxel-based approach called the functional diffusion map [18].
This analysis was further applied to rCBV maps and has been shown
to predict tumor response to standard therapy as well as distinguish
progression from a pseudoprogression in high-grade gliomas [16,17].
In the present study, we have found that only the voxel-based approach,
PRM, was sensitive enough to predict treatment response and that this
sensitivity showed no dependence on time of mid-treatment acqui-
sitions as well as tumor delineation. In general, patients who have a
larger fraction of their tumor with decreased rCBV values do worse
than patients who do not. One hypothesis for this finding may be that
a rapid drop in rCBV leads to a volume fraction more likely to be
hypoxic or alternatively to a reduction in the concentration of chemo-
therapeutic agent delivered to the tumor site and thus are more resistant
to chemoradiotherapy. Nevertheless, evaluation of a variety of possible
analytical techniques for assessing therapeutic response using a well-
defined cohort of high-grade glioma (HGG) patients has provided
unique insights into optimizing image analysis approaches for assess-
ment of tumor response.
In this present study, we realized the importance of noncontrast-
enhancing regions as defined by FLAIR as a complimentary metric to
T1-Gd images for tumor response to therapy as highlighted by the
RANO Working Group as well as the introduction of different
analytical techniques for evaluating rCBV data. We demonstrated
in a single site prospective clinical study that the PRM technique
was able to provide a metric capable of early prediction of patient
survival, whereas other analytical approaches showed no predictive
potential. Although using the same cohort of patients, these new
findings are distinctly different from results reported in our previous
studies. First, among the different analytic methods tested at various
mid-treatment time points and VOIs, only the PRMrCBV− signifi-
cantly correlated to patient survival. Previous analyses compared
the predictive value of PRMrCBV− only against the percentage change
Figure 5. Predictive value of imaging biomarkers. Kaplan-Meier survival plots for overall survival, presented as stratified by PRMrCBV− at
(A, B) week 1 or (C, D) week 3 after treatment initiation and using either (A, C) Gd-VOI or (B, D) FLAIR-VOI. Blue line indicates PRMrCBV−
lower than or equal to the cutoff and green line indicates PRMrCBV−more than the cutoff. The cutoff of 5.9% was defined as the mean of
the optimal cutoff calculated for each PRMrCBV− at a specific time interval post-therapy and VOI (Table 2).
Table 2. Survival Analysis.
Metric Time Point (Weeks) VOI (Mean Tumor Volume, cm3) AUC ROC P Value Cutoff Log-Rank Test
PRMrCBV− 1 Gd (37 ± 31) 0.754 .006 6.8 0.005
PRMrCBV− 1 FLAIR (104 ± 84) 0.727 .01 4.6 (−32%) <0.0001
PRMrCBV− 3 Gd (35 ± 27) 0.733 .008 6.8 (0%) <0.0001
PRMrCBV− 3 FLAIR (105 ± 86) 0.749 .005 5.3 (−22%) <0.0001
Note: Only metrics that could statistically predict 1-year survival, based on ROC curves, are presented and further analyzed.
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in the mean rCBV. Second, this voxel-based approach was found to
be very robust for patient treatment response stratification with neg-
ligible sensitivity in the optimal cutoff to the choice of VOI (volumes
delineated by Gd or FLAIR) or the time the rCBV map was acquired
during treatment (5.9 ± 1.1%; mean ± SD across optimal cutoffs for
PRMrCBV−). No such analysis was performed in our previous work.
PRM analysis applied to rCBV was shown to be a flexible (VOI and
time after start of treatment) and robust (a single cutoff is applicable)
early imaging response biomarker for patients with brain tumors.
Changes of tumor size over time are an important issue of the
PRM technique and it needs to be carefully checked. In our study,
no significant changes in tumor sizes were observed; the exception
was the change in tumor volume as defined by FLAIR-VOI between
weeks 0 and 1. We employed a rigid body registration algorithm for
our PRM analysis of rCBV data. Although nonlinear deformation in
the tumor may have occurred over the interval examinations, these
changes were small relative to local changes in rCBV values. The
rationale is that excessive deformation would cause erroneous PRM
values eliminating any predictive potential and ultimately resulting in
only noise from the PRM analysis. In fact, excessive imaging noise
and artifacts would also result in errors in the PRM values. Contrary
to all of this, PRM was the only metric predictive of overall survival.
By applying these techniques to a single cohort, imaging noise,
artifacts, and changes in tumor volume are essentially controlled. A
multivariate Cox regression analysis was performed to evaluate the
impact of the percentage change in tumor volume on the prediction
of the PRMrCBV− metric using the FLAIR-VOI at week 1. PRMrCBV−
was the only significant parameter for the regression model to predict
overall patient survival (P = .001 and P = .9 for PRMrCBV− and the
percentage change in tumor volume, respectively). Moreover, in this
same period, the percentage change of the tumor size was +6.5 ± 3.8%
(mean ± SEM) and is on the same order as the interobserver variability
for manual tracing of brain tumor (up to 15%) [31].
We have demonstrated that despite perfusion MRI showing prom-
ise as a surrogate biomarker of therapeutic response in patients with
glioma, the choice of analytical method greatly impacts the sensitivity
of the imaging biomarker. The PRM approach to analyzing imaging
data improves the accuracy of perfusion MRI as a biomarker of over-
all survival but is also insensitive to tumor VOIs and mid-treatment
time of acquisition. This study illustrates the importance of the
analytical method for assessing early prediction of treatment response
using MRI perfusion data. The application of PRM to blood perfu-
sion maps shows promise as an early and robust surrogate imaging
biomarker of treatment response in patients diagnosed with high-
grade glioma.
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